Pipeline

We have a diverse pipeline designed to make a meaningful difference for patients

We have a diverse pipeline designed to make a meaningful difference for patients

Our growing development pipeline of innovative new therapies is driven by the flexibility of our TransCon® technologies and our aim to improve patients' lives. We have multiple prodrug therapies in development. Each candidate is unique and designed to be a best-in-class therapy.

Endocrinology Rare Diseases1

Phase 1
Phase 2
Phase 3
TransCon hGH
Pediatric Growth Hormone Deficiency
(Greater China)1
Phase 3
Pediatric Growth Hormone Deficiency
(Japan)2
Phase 3
Adult Growth Hormone Deficiency
(Global)3
Phase 3
TransCon PTH
Adult Hypoparathyroidism
(North America & Europe)4
Phase 3
Adult Hypoparathyroidism
(Greater China)1
Phase 3
Adult Hypoparathyroidism
(Japan)5
Phase 3
TransCon CNP
Pediatric Achondroplasia
(North America, Europe, Oceania)6
Phase 2
Pediatric Achondroplasia
(Greater China)1
Phase 2

Oncology4

Phase 1
Phase 2
Phase 3
TransCon TLR7/8 Agonist
Monotherapy7
Phase 1
Combination Therapy7
Phase 1
TransCon IL-2 β/γ
Monotherapy8
Phase 1
Combination Therapy8
Phase 1

1 In development in Greater China through strategic investments in VISEN Pharmaceuticals
2 Japanese riGHt Trial
3 Global foresigGHt Trial
4 North American and European PaTHway Trial
5 Japanese PaTHway Japan Trial
6 North America, Europe, and Oceania AComplisH Trial
7 transcendIT 101 Trial
8 IL-βelieγe Trial

Explore

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.

Are you a U.S. resident?

If so, please confirm below to proceed to our U.S. website. If not, continue to our global website.

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.